Navigation Links
Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine
Date:5/22/2013

3 (7 diagnoses per 52,000 doses, compared to 4.24 expected). At the end of the study, when the diagnoses were confirmed by medical-record review, the risk of Kawasaki disease in the 28 days following PCV7 was 1 per 100,000 doses and 2 per 100,000 doses of PCV13. Although this difference was not statistically significant, the researchers note it warrants further studies. Researchers also emphasized that this is a statistical association and therefore may not represent a cause-and-effect relationship.

The CDC recommends all children ages 5 years and younger receive PCV13. The vaccine protects against pneumococcal disease, an infection caused by Streptococcus pneumoniae. The most common types of pneumococcal infections include middle-ear infections, sinus infections, lung infections, bloodstream infections and meningitis. According to the CDC, each year in the U.S. pneumococcal bacteria cause about 4,000 cases of bloodstream infections (bacteremia), meningitis, or other invasive disease in children younger than 5 years of age.

Researchers used medical records from the Vaccine Safety Datalink, a collaborative effort between the CDC and integrated care organizations, including Kaiser Permanente, to conduct the study. The Vaccine Safety Datalink project monitors immunization safety and addresses the gaps in scientific knowledge about any rare and serious events that occur following immunization.

This study is part of Kaiser Permanente's ongoing efforts to study the safety and effectiveness of vaccines. Last year, a Kaiser Permanente study conducted through the Vaccine Safety Datalink found the herpes zoster vaccine, also known as the shingles vaccine, is generally safe and well tolerated. Additionally late last year,

SOURCE Kaiser Permanente
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kaiser Permanente Ranks Highest in 2012 J.D. Power and Associates Employer Satisfaction Study for Second Year in a Row
2. My Health Manager Users More Likely to Remain Kaiser Permanente Members
3. Four Million People Choose Connectivity and Convenience with Kaiser Permanentes Personal Health Record
4. Kaiser Permanente Appoints Alexandra Morehouse as Vice President of Advertising and Brand Management
5. Kaiser Permanente Joins Rock Health to Support Digital Innovation in Health Care
6. Jack Cochran, MD, Executive Director of The Permanente Federation at Kaiser Permanente, named to National Quality Forum Board
7. Kaiser Permanente Members Share Stories of Survival for Februarys Heart Health Month
8. Kaiser Permanente Receives Award for Excellence in Medication Safety
9. Doug Bonacum of Kaiser Permanente Named to List of 50 Experts Leading the Field of Patient Safety
10. Nearly 30 Percent of Women Fail to Pick Up New Prescriptions for Osteoporosis, Kaiser Permanente Study Finds
11. Kaiser Permanente Study Finds Varied Reasons Why Patients Do Not Fill their Initial Statin Prescriptions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Japan , July 30, 2015 ... of the study to fulfill the post-marketing commitment ... the Pan European Multi-Database Bladder Cancer Risk ... retrospective matched cohort study, conducted in four European ... HCI) with up to 10 years of follow-up. ...
(Date:7/30/2015)... Calif. , July 30, 2015   ... to eliminate all preventable hospitalization, recently received confirmation ... its Remote Patient Intelligence (RPI) solution meets the ... FDA intends to exercise "Enforcement Discretion." ... not subject to further FDA regulatory requirements at ...
(Date:7/30/2015)... July 30, 2015  Lannett Company, Inc. (NYSE: ... at the Canaccord Genuity 35th Annual Growth Conference on ... the InterContinental Boston Hotel.  A webcast ... .  Listeners are encouraged to visit the web site ... the presentation to register, download and install any necessary ...
Breaking Medicine Technology:Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3
... YORK, June 20, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0558499/Top-Medical-Devices-and-Imaging-Technologies-2011.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Devices ... device and imaging technologies that have excellent ...
... VANCOUVER, British Columbia, June 17, 2011 Abattis Biologix Corporation ... commenced trading on the OTC Pink Sheets under the symbol ... the company proceeds with financing activities and the preparation of ... and other exchanges. Mike Withrow, CEO of Ab ...
Cached Medicine Technology:Reportlinker Adds Top Medical Devices and Imaging Technologies 2011 2Abattis Biologix Corporation Begins Trading on Pink Sheets 2
(Date:7/30/2015)... ... ... Quintessa Medical Spa is happy to offer patients the latest treatment for ... the elimination of excess tissue under the chin, referred to as submental fat. ... offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, Kybella was approved by the ...
(Date:7/30/2015)... ... 30, 2015 , ... The New Jersey Innovation Institute (NJII), ... of Health, has received a $2.9 million grant from the Office of the ... Health and Human Services (HHS). NJII will help the Department of Health ensure ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Bird B ... a new bird hazing system to repel pest birds from the AC ... diseases—including histoplasmosis, encephalitis, salmonella, meningitis, and toxoplasmosis, even the West Nile virus. When these ...
(Date:7/30/2015)... ... ... After conducting a nationwide executive search led by healthcare leadership solutions firm ... N.Y., has hired Gerard (Jerry) Walsh as Chief Executive Officer. Walsh assumed his new ... Walsh is an expert in organizational change, physician development, implementation of quality and patient ...
(Date:7/30/2015)... Springfield, Mo (PRWEB) , ... July 30, 2015 , ... ... home health and hospice care, announced today that it is hosting a free webinar ... St. Pierre, RN, BSN, MGA, HEALTHCAREfirst Consultant and former Vice President of Regulatory Affairs ...
Breaking Medicine News(10 mins):Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5Health News:HEALTHCAREfirst Announces Home Health Industry Regulatory Review Webinar 2
... CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: ... published by the Seattle Times reporting ... incorrectly reported that CellCyte ,closes.,In CellCyte,s August 14, ... its bioreactor business segment and generally described its ...
... Dec. 29 Watson Pharmaceuticals,Inc. (NYSE: ... branded pharmaceuticals,today announced that its subsidiary, Watson Laboratories, ... Food and Drug Administration on its,Abbreviated New Drug ... USP, 0.15 mg / 0.02 mg. Desogestrel/ethinyl,estradiol ...
... Priority ReviewEAST BRUNSWICK, N.J., Dec. 29 Savient ... announced that the U.S. Food and Drug Administration ... License Application (BLA) for pegloticase, a novel biological ... also granted the Company,s BLA with a priority ...
... Cross and Blue Shield of Oklahoma announced today the ... their next policy year. This change will not in ... always been available to children with autism. Blue Cross ... interests in the benefits and coverage of certain autism-related ...
... Dec. 29 Eastern Life & Health Insurance Company (ELH), ... EIHI ), announced today that it will add vision to ... include a vision insurance plan and a vision discount program, ... "Adding vision to ELH,s product portfolio enables employers to offer ...
... 29 Life for Relief and Development (LIFE), a ... the civilian victims of the recent conflict in Gaza. ... non-governmental organizations operating in the area, LIFE has obtained ... relief items to Gaza via a specially designated humanitarian ...
Cached Medicine News:Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 2Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 3Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 4Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 5Health News:Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R) 2Health News:Pegloticase BLA Filing Accepted for Priority Review by FDA 2Health News:Pegloticase BLA Filing Accepted for Priority Review by FDA 3Health News:Pegloticase BLA Filing Accepted for Priority Review by FDA 4Health News:Blue Cross and Blue Shield of Oklahoma Announces Autism Benefits 2Health News:Eastern Life & Health Introduces New Vision Product 2Health News:Eastern Life & Health Introduces New Vision Product 3
... of any biological activity but appears to ... of insulin. Although insulin and C-Peptide are ... fasting levels of C-Peptide are 5-10 fold ... the longer half-life of C-Peptide. The glucagon ...
... The Array Multifocal IOL was designed ... with independence from glasses in most situations. ... IOL is similar to that of a ... usually much better and about 19 in ...
Inquire...
... IgG Enzymelinked Immunosorbent Assays(ELISA) is intended for ... antibody to Measles Rubeola) virus in human ... for the determination of immune status. Paired ... demonstrate seroconversion or a significant rise in ...
Medicine Products: